KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Account Payables: 2017-2025

Historic Change in Account Payables for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to -$2.2 million.

  • Amneal Pharmaceuticals' Change in Account Payables fell 120.39% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 43.05%. This contributed to the annual value of $54.4 million for FY2024, which is 453.88% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Change in Account Payables stood at -$2.2 million for Q3 2025, which was down 134.07% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Account Payables ranged from a high of $34.1 million in Q4 2024 and a low of -$7.2 million during Q2 2021.
  • Its 3-year average for Change in Account Payables is $6.1 million, with a median of $4.1 million in 2024.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Change in Account Payables skyrocketed by 3,526.67% in 2021 and then slumped by 6,605.33% in 2022.
  • Amneal Pharmaceuticals' Change in Account Payables (Quarterly) stood at $1.6 million in 2021, then tumbled by 124.94% to -$407,000 in 2022, then skyrocketed by 1,493.61% to $5.7 million in 2023, then spiked by 501.23% to $34.1 million in 2024, then slumped by 120.39% to -$2.2 million in 2025.
  • Its Change in Account Payables was -$2.2 million in Q3 2025, compared to $6.4 million in Q2 2025 and -$1.1 million in Q1 2025.